Bevacizumab: the first FDA-approved angiogenesis inhibitor in the treatment of non-small cell lung cancer

Published on January 6, 2009 Archived on February 25, 2021   54 min

A selection of talks on Cancer


Quiz available with full talk access. Request Free Trial or Login.

Hide

Bevacizumab: the first FDA-approved angiogenesis inhibitor in the treatment of non-small cell lung cancer

Embed in course/own notes